Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin.
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin.

H C Meissner, D R Fulton, J R Groothuis, R L Geggel, G R Marx, V G Hemming, T Hougen, D R Snydman;H C Meissner;D R Fulton;J R Groothuis;R L Geggel;G R Marx;V G Hemming;T Hougen;D R Snydman;
Antimicrobial agents and chemotherapy 1993 Vol. 37 pp. 1655-
115
snydman1993antimicrobialcontrolled

Abstract

We performed a randomized, controlled trial of intravenous immune globulin (respiratory syncytial virus [RSV] neutralizing [Nt] antibody titer of 1:950 in 5% solution) to evaluate protection against RSV-induced disease over two respiratory virus seasons. ...

Keywords

Access

DOI:
10.1128/aac.37.8.1655
URL:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC188036...

Citation

ID: 119378
Ref Key: snydman1993antimicrobialcontrolled
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
119378
Unique Identifier:
10.1128/aac.37.8.1655
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet
Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store